Linked Life Data

7536945

Source:http://linkedlifedata.com/resource/pubmed/id/7536945

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1995-5-25
pubmed:abstractText
Risperidone and remoxipride are recently introduced atypical antipsychotics, with clinical efficacy comparable to that of classical antipsychotics but lower propensity to induce extrapyramidal side effects (EPS). It is unclear whether these properties relate to weak dopamine D2 receptor blockade in vivo, as has been suggested for the archetypal atypical antipsychotic clozapine. We have used 123I-IBZM single photon emission tomography (SPET) to characterize the patterns of striatal D2 receptor binding in vivo in DSMIII-R-diagnosed schizophrenic and schizo-affective patients treated with either risperidone (n = 6) or remoxipride (n = 4) but predominantly EPS free. These groups were compared to age- and BPRS- matched subjects from a previously reported D2 receptor binding database of patients treated with clozapine (n = 10) and classical antipsychotics (n = 10). Patients on risperidone and remoxipride had high levels of D2 receptor blockade, comparable to those of patients on classical antipsychotics, and significantly greater than those obtained with clozapine-treated patients (risperidone versus clozapine, P < 0.005; remoxipride versus clozapine, P < 0.025). These results suggest high levels of striatal D2 receptor occupancy in association with remoxipride and risperidone treatment and argue against modest D2 antagonism as the explanation for the low incidence of EPS associated with these drugs.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0033-3158
pubmed:author
pubmed:issnType
Print
pubmed:volume
117
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
55-61
pubmed:dateRevised
2009-9-29
pubmed:meshHeading
pubmed-meshheading:7536945-Adult, pubmed-meshheading:7536945-Antipsychotic Agents, pubmed-meshheading:7536945-Basal Ganglia, pubmed-meshheading:7536945-Benzamides, pubmed-meshheading:7536945-Cerebral Cortex, pubmed-meshheading:7536945-Female, pubmed-meshheading:7536945-Humans, pubmed-meshheading:7536945-Image Processing, Computer-Assisted, pubmed-meshheading:7536945-Iodine Radioisotopes, pubmed-meshheading:7536945-Isoxazoles, pubmed-meshheading:7536945-Male, pubmed-meshheading:7536945-Middle Aged, pubmed-meshheading:7536945-Neostriatum, pubmed-meshheading:7536945-Piperidines, pubmed-meshheading:7536945-Psychiatric Status Rating Scales, pubmed-meshheading:7536945-Psychotic Disorders, pubmed-meshheading:7536945-Pyrrolidines, pubmed-meshheading:7536945-Receptors, Dopamine D2, pubmed-meshheading:7536945-Remoxipride, pubmed-meshheading:7536945-Risperidone, pubmed-meshheading:7536945-Schizophrenia, pubmed-meshheading:7536945-Tomography, Emission-Computed, Single-Photon
pubmed:year
1995
pubmed:articleTitle
Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
pubmed:affiliation
Department of Psychological Medicine, Institute of Psychiatry, Denmark Hill, London, UK.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't